|
|
Article: Adjuvanted Formulation of sanofi pasteur H5N1 Pandemic Influenza Vaccine Candidate Demonstrates Significant Immune Response.
- Article from:
- PR Newswire
- Article date:
- May 10, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LYON, France, May 10 /PRNewswire-FirstCall/ -- A study published online in The Lancet on May 11 demonstrated that multiple dosage formulations of a candidate H5N1 influenza vaccine developed by sanofi pasteur were well- tolerated and generated an immune response, with and without adjuvant. Of the formulations being tested, an alum-adjuvanted 30 microgram dosage generated the most substantive immune response (66.7% HI [haemaggluttination inhibition] seroconversion rate after two vaccinations) and was well-tolerated in the clinical study.
This is the first trial of an H5N1 pre-pandemic influenza vaccine candidate comparing vaccines with and without adjuvants. A ...